ReviewDiscover nano2026
Bridging cancer therapies: the role of magnetic nanoparticles in combination cancer therapy.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.Breast cancer research : BCR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the efforts of the medical and research community for effective treatments, cancer is one of the leading causes of death worldwide. Cancer cells' enduring resistance is a significant cause of treatment failure. One of the most effective approaches proposed to overcome this resistance is a combination therapy. This is a transformative strategy by integrating complementary techniques such as radiation therapy, immunotherapy, photothermal treatment, photodynamic therapy, and hyperthermia, as well as combined with chemotherapy. Numerous studies have investigated the synergistic effects of these therapies to identify the most effective methods for cancer therapy. Researchers also found that magnetic nanoparticles can play a central and innovative role by enhancing the synergistic interactions of combination therapies. Their magnetic reactivity, high surface-to-volume ratio, and surface functionalization enable precise tumor-selective targeting, controlled drug delivery, and efficient conversion of light into heat. They can act as mediators, providing significant benefits when two or more therapeutic methods are used simultaneously. This can enhance their effectiveness. Mechanistically, magnetic nanoparticle-mediated hyperthermia enhances chemotherapy efficacy by elevating tumor temperatures, increasing membrane permeability, and promoting tumor sensitization to radiotherapy. The production of reactive oxygen species (ROS) in cancerous cells, the exacerbation of oxidative damage during photothermal therapy, and the enhancement of immune activation in combined immunotherapeutic approaches improve the effectiveness of chemotherapy. Biocompatible materials such as PEG, chitosan, and dextran can further stabilize these nanoparticles, and ligand functionalization enhances selective tracking of cancer cells. This article provides a comprehensive review of the multifunctional role of magnetic nanoparticles across diverse therapeutic combinations, including radiotherapy, immunotherapy, photothermal therapy, photodynamic therapy, and hyperthermia. It will help those interested in this research topic to comprehensively and validly compare and investigate various studies, make informed decisions, and introduce next-generation Magnetic nanoparticle-based combination therapies for cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.